Solid and hematological tumor

Matthias Ocker: Novel small molecule MCL-1 inhibitor in vivo clearance and robust efficacy in solid and hematological tumor models

Matthias Ocker, Head of Experimental Medicine at Tacalyx GmbH, shared on X:

“I’m excited to share our recent publication on a novel small molecule MCL-1 inhibitor now out in Nature Cancer. Thanks to an outstanding team to accomplish this.”

solid and hematological tumor

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

Authors: Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T. Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer Roth, Douglas Daniels, Virendar K. Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R. Golub

solid and hematological tumor

Source: Matthias Ocker/X

Brian Hubbard cancer Christopher T. Lemke Douglas Daniels Franziska Siegel Georgios Kosmidis Guillaume Poncet-Montange Guo Wei James McFarland Jennifer Roth Kai Thede Karl Ziegelbauer Katrin Nowak-Reppel Kyle Davis Matthias Ocker Michael Serrano-Wu Nature Cancer Nicolas Werbeck OncoDaily Oncology Sabine Pilari solid and hematological tumors Stefan Kaulfuss Stephan Menz Todd R Golub Ulrike Rauh Virendar K. Kaushik Weiqun Zhang